Tobira Therapeutics Inc. Completes Senior Management Team With Key Strategic Hires in Finance, Clinical and Pharmaceutical Sciences
9/10/2012 9:12:06 AM
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tobira Therapeutics, Inc., developer of innovative antiretroviral therapies for HIV, announced the addition of three highly accomplished executives in the finance, clinical and pharmaceutical sciences functions. Joining the company are Caroline Loewy as Executive Vice President and Chief Financial Officer, Jeff Enejosa, M.D., as Senior Director, Clinical Research, and Mark Menning as Director, Pharmaceutical Sciences. These key hires complete Tobira’s experienced team, capable of advancing its lead compound, cenicriviroc (CVC or TBR-652), rapidly through the final stages of clinical development. Cenicriviroc is a novel, oral, once-daily, fixed-dose combinable, dual inhibitor of chemokine receptors CCR5 and CCR2. Tobira is currently evaluating cenicriviroc in a Phase 2b trial for the treatment of HIV-1 infection.
comments powered by